🔎 Trials Near Me

Home › Kanser sa Tiyan › Massachusetts

Pag-aaral pangklinika para sa Kanser sa Tiyan sa Massachusetts

34 pag-aaral para sa Kanser sa Tiyan ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

Distance-Based Exercise to Preserve Function and Prevent Disability

  • Dana-Farber Cancer Institute, Boston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07059884

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Dana-Farber Cancer Institute - Oncology Department, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06760819

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 19 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06586957

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07578571

IKS014 in Advanced Solid Tumors That Express HER2

  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05872295

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Tufts Medical Center, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07114601

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07213791

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

  • Massachusetts General Hospital, Boston
  • UMass/Shields, Worcester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07217704

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT06293898

Resilience and Equity in Aging, Cancer, and Health (REACH)

  • Dana-Farber Cancer Institute, Boston
Nagre-recruit
Edad 65 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04674267

A Phase 1/1b Study of IAM1363 in HER2 Cancers

  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06253871

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  • Dana Farber Cancer Institute, Boston
  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07070232

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07070466

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

  • Mass General Cancer Center, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT07227168

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

  • Massachusetts General Hospital Cancer Center, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT05592626

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  • Tufts Medical Center, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT06731478

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

  • Massachusetts General Hospital - Dana Farber, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT03526835

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • Beth Israel Deaconess Medical Center, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06131840

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Massachusetts General Hospital, Boston
  • Brigham & Women's Hospital, Boston
  • Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
  • at 3 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

  • Dana-Farber Cancer Institute, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT07675967

Integrated Cancer Repository for Cancer Research

  • Holyoke Medical Center, Holyoke
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

  • I-Mab Site 1002, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 14, 2026 · NCT07432295

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT06239194

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT06395519

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

  • Mass General Hospital, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 5, 2026 · NCT04900818

CONFIRM: Magnetic Resonance Guided Radiation Therapy

  • Brigham & Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT04368702

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 16, 2026 · NCT02584244

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Worcester
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

  • Dana Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2025 · NCT05941507

Comprehensive Outcomes for After Cancer Health

  • Dana Farber Cancer Institute, Boston
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 11, 2024 · NCT05349227

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.